Compare TRMK & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRMK | VRDN |
|---|---|---|
| Founded | 1889 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | 1987 | N/A |
| Metric | TRMK | VRDN |
|---|---|---|
| Price | $41.03 | $33.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $42.67 | $41.17 |
| AVG Volume (30 Days) | 265.3K | ★ 1.3M |
| Earning Date | 01-27-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | ★ 10.82 | N/A |
| EPS | ★ 3.66 | N/A |
| Revenue | ★ $773,338,000.00 | $70,789,000.00 |
| Revenue This Year | $58.33 | $26,257.62 |
| Revenue Next Year | $4.57 | $4.54 |
| P/E Ratio | $11.15 | ★ N/A |
| Revenue Growth | 55.58 | ★ 23340.07 |
| 52 Week Low | $29.77 | $9.90 |
| 52 Week High | $43.29 | $34.29 |
| Indicator | TRMK | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 53.37 | 58.30 |
| Support Level | $40.15 | $31.26 |
| Resistance Level | $43.29 | $34.29 |
| Average True Range (ATR) | 1.01 | 1.35 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 43.62 | 76.13 |
Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).